Inj olipudase alfa-rpcp 1mg
Products billed under this code include Xenpozyme.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Xenpozyme.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Xenpozyme | Genzyme Corporation | 58468-0050-01 | 20 | $8,095.68 |
| Xenpozyme | Genzyme Corporation | 58468-0051-01 | 4 | $1,619.136 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $404.784 | −$0.163 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted September 17, 2026 |
| 3Q26 | $404.947 | +$9.349 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted September 15, 2026 |
| 2Q26 | $395.598 | +$0.078 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted September 15, 2026 |
| 1Q26 | $395.52 | +$1.859 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted September 15, 2026 |
| 4Q25 | $393.661 | −$0.162 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted September 8, 2026 |
| 3Q25 | $393.823 | +$12.586 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted March 10, 2026 |
| 2Q25 | $381.237 | −$0.342 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted March 10, 2026 |
| 1Q25 | $381.579 | −$0.981 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted December 19, 2025 |
| 4Q24 | $382.56 | +$0.727 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted June 11, 2025 |
| 3Q24 | $381.833 | +$5.253 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted June 11, 2025 |
| 2Q24 | $376.58 | −$0.385 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted March 11, 2025 |
| 1Q24 | $376.965 | −$0.148 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted December 19, 2024 |
| 4Q23 | $377.113 | −$0.395 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted October 10, 2024 |
| 3Q23 | $377.508 | −$1.018 | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted June 5, 2024 |
| 2Q23 | $378.526 | – | 1 MG | Inj olipudase alfa-rpcp 1mg | v1, posted February 23, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.